Open AccessS0704 Treatment Outcome of Tofacitinib Dose Reduction to 5 mg BID vs Remaining on 10 mg BID in Patients With UC Who Were in Stable Remission on 10 mg BID: 6-Month Data From the Double-Blind, Randomized RIVETING Study
Author(s) -
Séverine Vermeire,
Chinyu Su,
Nervin Lawendy,
Taku Kobayashi,
William J. Sandborn,
David T. Rubin,
Irene Modesto,
Sean Gardiner,
Nicole Kulisek,
Haiying Zhang,
Wenjin Wang,
Julián Panés
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000704864.11978.92
Subject(s) - tofacitinib , medicine , clinical endpoint , randomized controlled trial , gastroenterology , adverse effect , surgery , rheumatoid arthritis